Biologics in Otolaryngology: Past, Present, and Future.
Allergy
Biologics
Cancer
Immunotherapy
Monoclonal antibodies
Nasal polyposis
Otolaryngology
Rhinosinusitis
Journal
Otolaryngologic clinics of North America
ISSN: 1557-8259
Titre abrégé: Otolaryngol Clin North Am
Pays: United States
ID NLM: 0144042
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
pubmed:
13
6
2021
medline:
26
11
2021
entrez:
12
6
2021
Statut:
ppublish
Résumé
Biologics have been widely adopted in multiple subspecialties of otolaryngology. This article provides an overview of past, present, and future uses of biologics in otolaryngology with emphasis on allergic rhinitis, chronic rhinosinusitis with polyposis, head and neck squamous cell carcinoma, salivary and skull base tumors, hearing loss, and other otologic disorders.
Identifiants
pubmed: 34116845
pii: S0030-6665(21)00049-9
doi: 10.1016/j.otc.2021.04.001
pii:
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
675-687Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure S.K. Wise: consultant for NeurENT, Stryker; advisory board for OptiNose, SinopSys Surgical, ALK-Abello, and Genentech. N.C. Schmitt: advisory board for Checkpoint Surgical; book royalties from Plural Publishing. A. Monfared: none.